NOVEMBER'S BEST FEATURED EDITORIAL An End-To-End Automated HTP Platform For Cell Line Optimization Bristol Myers Squibb's high-throughput stable CHO platform produces high-titer, high-quality material in a fraction of the conventional timeline. Sensitive Critical Starting Materials Need A 'Just-In-Data' Approach Here's a blueprint for transforming the fragmented, high-risk interface between vector and cell therapy platforms into a unified, predictable, and compliant system.